The effectiveness of complex therapy using the injectable form of chondroitin sulfate and sodium hyaluronate with osteoarthritis of the knee joint


Cite item

Full Text

Abstract

Aim. The study on the effectiveness of complex therapy for osteoarthritis (OA) of the knee joint was conducted in real clinical practice. Materials and methods. The survey involved 125 patients aged fr om 50 to 70 years (25 men and 100 women) with a diagnosis of knee joint OA (the III roentgenologic Kellgren-Lawrence stage).The average age of the patients was 62±3.21, the average duration of the disease - 9.4±2.8 years. Patients were randomly assigned to three groups of 35 people, the control group had 20 patients. Group 1 patients received non - steroidal anti - inflammatory drugs (NSAIDs) + Injectran(Chondroitin sulfate) 200 mg intramuscularly (I.M.) every other day No. 25.In group 2, patients received NSAIDs + Fermatron 1% 2 ml with an interval of 7 days intra - articularly (I.A.) No. 3. In group 3 - NSAIDs + Injectran 200 mg (I.M.) every other day No. 25 + Fermatron 1% 2 ml with an interval of 7 days (I.A.) No. 3. In the control group (20 people), patients received only NSAIDs. Evaluation of the symptoms was carried out using the WOMAC index before the start of thetherapy, after 8 and 12 weeks of treatment. The intensity of pain while walking was estimated on a visual analogue scale. Results. In the groups that received Injectran (I; group 1) or Fermatron (F; group 2), the dynamics of pain while walking reduction was comparable and had slightly more than 30% in both groups, the figures are reliable in comparison withinitial data (p<0.01). In group 3, wh ere both Injectran + Fermatron (I+F) were used, the pain while movingdecreased by more than 50% in comparison with initial data, i.e. combined use of two medications at the same time allowed to improve the results of treatment by 1.5 times.Patients' need for NSAIDs before and after therapy was also investigated. In all the groups, patients were able to reduce the dose of NSAIDs.In the control group, 80% of patients had the same dose of NSAIDs by the end of the 8th week, whereas in group 3 (I+F) - only 5.7%, in group 2 (F) - 17.1%, in group 1 (I) - 11.5%. Intergroup differences are valid (p<0.001). The number of patients who completely withdraw NSAIDs was the largest in group 3 (I+F; 22.8%), which is 2 times more than in group 2 (F; 11.4%) and 4 times more than in group 1 (I; 5.7%), the differences are valid (p<0.01). Conclusion. By the end of the therapy, the decline in the WOMAC index was mostly in group 3 (I+F) - more than 50%, in the 1st (I) and 2nd (F) groups - more than 40%, in the control group - 20%. After 12 weeks in all the groups there was a tendency to maintain and even increase the effect of the therapy.

About the authors

E A Belyaeva

Tula State University, Medical Institute

Email: belyaevael@yandex.ru
д.м.н., проф. каф. внутренних болезней Tula, Russia

O S Avdeeva

Tula State University, Medical Institute

ассистент каф. внутренних болезней Tula, Russia

References

  1. Балабанова Р.М., Эрдес Ш.Ф. Распространеность ревматических заболеваний в Росии в 2012-2013 гг. Научно - практическая ревматология. 2015;53(2):120-4.
  2. Фаломеева О.Н., Галушка Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в Росии и США. Научно - практическая ревматология. 2008;46(4):4-13.
  3. Шумада И.В. Диагностика и лечение дегенеративно - дистрофических поражений суставов. Київ: Здоров’я, 1990.
  4. Xia B, Di Chen, Zhang J, et al. Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcif Tissue Int. 2014;95(6):495-505.
  5. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013;21:16-21.
  6. Дубиков А.И. Остеоартроз: старая болезнь, новые подходы. Современная ревматология. 2013;(2):82-8.
  7. Каратеев А.И., Лила А.М. Остеоартрит: современная клиническая концепция и некоторые перспективные терапевтические подходы. Научно - практическая ревматология. 2018;56(1):70-81.
  8. Robinson L, Wang Q, et al. Low - grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(10):580-92.
  9. Лила А.М., Громова О.А., Торшин И.Ю., Назаренко А.Г., Гоголев А.Ю. Молекулярные эффекты хондрогарда при остеоартрите и грыжах межпозвоночного диска. Неврология. Нейропсихиатрия, психосоматика. 2017;9(3):88-97.
  10. Васильева Л.В., Евстратова Е.Ф., Никитин А.В., Бурдина Н.С., Барсукова Н.А. «Ступенчатая» терапия хондроитина сульфатом у больных остеоартритом на поликлиническом этапе. Современная ревматология. 2017;11(3):77-80.
  11. Каратеев А.Е., Лила А.М. Российский опыт применения инъекционных форм хондроитина сульфата и глюкозамина сульфата: обзор клинических исследований. Современная ревматология. 2018;12(1):33-40.
  12. Иммаметдинова Г.Р, Чичасова Н.В. Хондроитина сульфат при заболеваниях опорно - двигательного аппарата: эффективность и безопасность с позиций доказательной медицины. Русский медицинский журнал. 2016;22:1481-8.
  13. Ronca F, Palmieri L, Panicucci P, Ronca G. Antiinflammatori activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998 May 6;(Suppl A):14-21.
  14. Bruyere O, Cooper C.C, Pelletier J.P, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe andinternationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44(3):253-63.
  15. Bruyere O, Cooper C.C, Pelletier J.P, et al. A consensus statement on the the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Algorithm for the management of knee osteoarthritis - From evidence - based medicine to the real - life setting. Semin Arthritis Rheum. 2016;45(4):3-11.
  16. Епифанов В.А. Остеохондроз позвоночника: диагностика, лечение, профилатика. Изд. 2. М.: МЕДпресс - информ, 2004.
  17. Федорищев И.А. Гиалуроновая кислота. Монография. М., 2011; 237 с.
  18. Henrotin Y, Raman R, Richette P, et al. Consensus statement jn viscosupplementation with hyaluronic acid for the management of OA. Semin Arthritis Rheum. 2015;45(2):140-9.
  19. Yasui T, Acatsuca M, Tobetto K, et al. The effect of hyaluronan on interleukin-1 alpha - induced prostaglandin E2 production in human OA sinovial cells. Agents Actions.1992;37(1-2):155-6.
  20. Campo G.M, Avenoso A, Campo S, et al. Chondroitin-4-sulfate ingibits NF-ḱB translocation and caspase fctivation in collagen - induced arthritis in mice. Osteoarthritis Cartilage. 2008 Dec;16(12):1474-83.
  21. Volpi N. Anti - inflammatory activity of chondroitin sulfate: new functions from an old natural macromolecule. Inflammopharmacology. 2011 Dec;19(6):299-306.
  22. Imada K, Oka H, Kawasaki D, et al. Antiarthritic action mechanisms of natural chondroitin sulfate in human articular chondrocytes and synovial fibroblasts. Biol Pharm Bull. 2010;33(3):410-4.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies